Lung Cancer Organoids: The Rough Path to Personalized Medicine

Lung cancer is the leading cause of cancer death worldwide. Despite significant advances in research and therapy, a dismal 5-year survival rate of only 10-20% urges the development of reliable preclinical models and effective therapeutic tools. Lung cancer is characterized by a high degree of hetero...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-07, Vol.14 (15), p.3703
Main Authors: Rossi, Rachele, De Angelis, Maria Laura, Xhelili, Eljona, Sette, Giovanni, Eramo, Adriana, De Maria, Ruggero, Cesta Incani, Ursula, Francescangeli, Federica, Zeuner, Ann
Format: Article
Language:English
Subjects:
Biomarkers
Cell culture
Cystic fibrosis
Drug testing
Histology
Kinases
Lung cancer
Lymphatic system
Medical prognosis
Medical research
Mutation
Organoids
Patients
Precision medicine
Review
Spheroids
Stem cells
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading cause of cancer death worldwide. Despite significant advances in research and therapy, a dismal 5-year survival rate of only 10-20% urges the development of reliable preclinical models and effective therapeutic tools. Lung cancer is characterized by a high degree of heterogeneity in its histology, a genomic landscape, and response to therapies that has been traditionally difficult to reproduce in preclinical models. However, the advent of three-dimensional culture technologies has opened new perspectives to recapitulate in vitro individualized tumor features and to anticipate treatment efficacy. The generation of lung cancer organoids (LCOs) has encountered greater challenges as compared to organoids derived from other tumors. In the last two years, many efforts have been dedicated to optimizing LCO-based platforms, resulting in improved rates of LCO production, purity, culture timing, and long-term expansion. However, due to the complexity of lung cancer, further advances are required in order to meet clinical needs. Here, we discuss the evolution of LCO technology and the use of LCOs in basic and translational lung cancer research. Although the field of LCOs is still in its infancy, its prospective development will likely lead to new strategies for drug testing and biomarker identification, thus allowing a more personalized therapeutic approach for lung cancer patients.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14153703